Health
Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes – News-Medical.Net
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels
Reviewed by Emily Henderson, B.Sc.Sep 25 2020
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.
The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of maj…
-
General12 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News12 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News21 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General19 hours agoCrowe toasts talkback titan for platforming ‘voiceless’